Stocks closed mixed as blue chips hit another record high but tech names tumbled on the potential for tighter U.S. restrictions on chip sales to China.
The U.S. presidential campaign season is already sending shockwaves through capital markets, notes José Torres, senior economist at Interactive Brokers.
"Semiconductor shares are getting hammered on news that Trump isn't happy with the technology sector's warmth toward Beijing," Torres writes in a note to clients. "Meanwhile, President Biden is rushing to potentially implement the harshest of penalties to chip firms that trade with China to toughen up on the geopolitical front and possibly shore up his dwindling odds of reelection."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Concerns about additional curbs on sales of chips to China sent semiconductor stocks reeling. Magnificent 7 stock Nvidia (NVDA) dropped 6.6%, with Broadcom (AVGO, -7.9%), Advanced Micro Devices (AMD, -10.2%), Micron Technologies (MU, -6.3%) and several other sector names moving in sympathy.
As a result, the tech-heavy Nasdaq Composite tumbled 2.8% to settle at 17,996, while the broader S&P 500 fell 1.4% to 5,588. The blue-chip Dow Jones Industrial Average, however, set its 22nd record close or the year with a 0.6% gain to 41,198.
Today's divergent market action is raising questions about the sustainability of the current bull market. As Interactive Brokers' Torres notes, much of 2024's equity gains have come from "a handful of names currently under direct threat" from political campaigning.
"An important question is if the rest of the market, which generally lacks thrilling tales on a relative basis, can offset the waning momentum in the Magnificent 7 stocks," the economist says.
J&J helps the Dow
Johnson & Johnson (JNJ, +3.7) was a leading gainer among all 30 Dow Jones stocks after posting better-than-expected earnings. The pharmaceutical giant reported earnings per share (EPS) of $2.82 for the second quarter vs analysts' average estimate of $2.71. Revenue topped $22.3 billion, which was essentially in line with estimates.
Although Johnson & Johnson has long been one of the best dividend stocks for dependable dividend growth, its returns have been less than stellar. Indeed, JNJ trails the broader market for the year to date and has generated negative annualized total returns for the past one- and three-year periods.
Acquisitions, spin-offs and other moving parts make it tough for analysts to update their models. That's partly why the Street is sort of split on the JNJ at current levels.
Of the 23 analysts covering JNJ surveyed by S&P Global Market Intelligence, seven rate it at Strong Buy, five say Buy and 11 have it at Hold. That works out to a consensus recommendation of Buy, albeit with tepid conviction at best.
Related content
- Why Amazon Stock Is the Biggest Bargain on Amazon Prime Day
- If You'd Put $1,000 Into Amazon Stock 20 Years Ago, Here's What You'd Have Today
- All 30 Dow Jones Stocks Ranked: The Pros Weigh In
-
Stock Market Today: Dow Rises 854 Points From Its Intraday LowIf there's one thing markets hate, it's uncertainty. But uncertainty is all they're getting these days.
-
Are You a Retirement Millionaire Too Scared To Spend?If you are too scared to spend money in retirement, you may be saddled with regret. Here are three ways to safely enjoy your sizable retirement nest egg.
-
Stock Market Today: Dow Rises 854 Points From Its Intraday LowIf there's one thing markets hate, it's uncertainty. But uncertainty is all they're getting these days.
-
Seven Questions to Ask When Evaluating Personal Loan OptionsTaking out a personal loan too hastily could lock you into unfavorable terms with an untrustworthy lender. Ask these questions before signing anything.
-
How Much Does Being Rich Matter in Retirement?After a certain point, having more money in retirement won't make you any happier, new research shows. Instead, physical health, a sense of purpose, and a minimal amount of non-mortgage debt are more relevant.
-
The Three Biggest Fears Keeping Retirees Up at NightHere are the steps you can take to put those fears to rest and retire with confidence so you can relax and enjoy the life you've planned.
-
What Can a Donor-Advised Fund Do for You? (A Lot)DAFs and private foundations go about helping charities (and those who donate) in different ways. Each comes with its own benefits and restrictions to navigate.
-
Estate Planning When You Have International AssetsEstate planning gets tricky when you have assets and/or beneficiaries outside the U.S. To avoid costly inheritance mistakes, it pays to understand the basics.
-
Microsoft Stock: Innovation Spurs Its 100,000% ReturnMicrosoft's ability to recognize the "next big thing" has allowed sales – and its share price – to grow exponentially over the years.
-
Three Essential Estate Planning Steps to Protect Your Nest EggAfter dedicating years to building your wealth and securing your future, make sure your assets are protected and your loved ones are provided for in the future.
